%PDF-1.4
%
22 0 obj
<>
endobj
19 0 obj
<>
endobj
78 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2003-04-09T16:47:32Z
2024-03-28T13:20:32-07:00
QuarkXPressª 4.11: AdobePS 8.6 (219)
2024-03-28T13:20:32-07:00
application/pdf
Heather
2002-679.may
uuid:b3a349f3-1dd1-11b2-0a00-f308275d6100
uuid:b3a349f5-1dd1-11b2-0a00-aa0000000000
endstream
endobj
8 0 obj
<>
endobj
9 0 obj
<>
endobj
23 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
1 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
4 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
88 0 obj
[92 0 R]
endobj
89 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
BT
/CS0 cs 0 0 0 1 scn
/GS1 gs
/T1_0 1 Tf
-0.00011 Tc 0.1627 Tw 10 0 0 10 54 713.1616 Tm
(response leading to immunologically mediated osteoartic-)Tj
-0.0022 Tw 0 -1.2 TD
(ular complications, and can therefore be included within the)Tj
0.0432 Tw T*
[(category of \322reactive arthritis.\323 However)39.7 (, given our sample)]TJ
0.3002 Tw T*
(size, with just 9% reactive arthritis, it is not presently)Tj
0.0397 Tw T*
(possible to determine whether this allele is or is not associ-)Tj
0.13879 Tw T*
[(ated with this type of arthritis. )17.6 (The association, therefore,)]TJ
0.293 Tw T*
(has been established for all the osteoarticular forms of)Tj
0.02499 Tw T*
(human brucellosis.)Tj
0.12061 Tw 1.2 -1.2 Td
(Thus, our results show for the first time an association)Tj
0.31841 Tw -1.2 -1.2 Td
[(between HLA)-513.6 (antigens and osteoarticular complications)]TJ
0.0006 Tc 0.3743 Tw T*
(after infection with )Tj
/T1_1 1 Tf
0.37421 Tw 9.0515 0 Td
(B. melitensis)Tj
/T1_0 1 Tf
5.4939 0 Td
(. Determining genetic)Tj
-0.00011 Tc 0.2384 Tw -14.5453 -1.2 Td
(markers in this disease might enable us to know which)Tj
0.3147 Tw T*
(patients may be susceptible to developing more severe)Tj
-0.02679 Tw T*
[(forms of the disease. In summary)64.8 (, pending lar)17.7 (ger studies, we)]TJ
0.18311 Tw T*
(suggest that the HLA-B*39 allele is a marker of disease)Tj
0.0849 Tw T*
(susceptibility in the complicated focal osteoarticular forms)Tj
0.02499 Tw T*
(of human brucellosis.)Tj
/T1_2 1 Tf
0 Tw 0 -2.4 TD
(ACKNOWLEDGMENT)Tj
/T1_0 1 Tf
0.13969 Tw 8 0 0 8 54 487.1616 Tm
(The authors thank Ian Johnstone for his help with the English language)Tj
0.02499 Tw 0 -1.25 TD
(version of the manuscript.)Tj
/T1_2 1 Tf
0 Tw 10 0 0 10 54 453.1616 Tm
(REFERENCES)Tj
/T1_0 1 Tf
0.02499 Tw 8 0 0 8 61 443.1616 Tm
[(1.)-875.1 (Centro Nacional de Epidemilogia \(6/04/98\) y del Registro de)]TJ
1.675 -1.25 Td
[(SVEA. )54.8 (Annual report 1997. Malaga, Spain: Servicio de Salud)]TJ
T*
(Publica, Delegacion Provincial de Salud de Malaga; 1997.)Tj
-1.675 -1.25 Td
[(2.)-875.1 (Kaslow R, Colin )54.8 (A, Simon D. Reiter)-37 (\325)55.1 (s syndrome and reactive)]TJ
1.675 -1.25 Td
[(arthritis following Salmonella heidelber)17.7 (g gastroenteritis [letter].)]TJ
T*
(Arthritis Rheum 1980;23:702.)Tj
-1.675 -1.25 Td
[(3.)-875.1 (Hondika L, G\232mor B, Meretey K, et al. HLA-B27-associated)]TJ
1.675 -1.25 Td
(spondyloarthritis in chronic brucellosis [letter]. Lancet 1978;1:499.)Tj
31.325 42.671 Td
[(4.)-875.1 (Alarcon G, Bocanegra P)110.7 (, Gotuzzo E, et al. Reactive arthritis)]TJ
1.675 -1.25 Td
[(associated with brucellosis: HLA)-220.2 (studies. J Rheumatol 1981;)]TJ
0 Tw T*
(8:621-5.)Tj
0.02499 Tw -1.675 -1.25 Td
[(5.)-875.1 (Alarcon G, Gotuzzo E, Hinostroza S, Carrillo C, Bocanegra P)110.7 (,)]TJ
1.675 -1.25 Td
[(Espinoza L. HLA)-220.2 (studies in brucellar spondylitis. Clin Rheumatol)]TJ
0 Tc 0 Tw T*
(1985;4:312-4.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(6.)-875.1 (Caballero )54.8 (A, Bravo MJ, Nieto )54.8 (A, Colmenero JD, )54.8 (Alonso )54.8 (A, Mart\222n)]TJ
1.675 -1.25 Td
[(J. )17.7 (TNF)73.9 (A)-220.1 (promoter polymorphism and susceptibility to brucellosis.)]TJ
T*
(Clin Exp Immunol 2000;121:1-5.)Tj
-1.675 -1.25 Td
[(7.)-875.1 (Khan MA, Kushner I, Braun )17.7 (WE. B27-negative HLA-Bw16 in)]TJ
1.675 -1.25 Td
(ankylosing spondylitis. Lancet 1978;1:1370-1.)Tj
-1.675 -1.25 Td
[(8.)-875.1 (Y)99.8 (amaguchi )54.8 (A, )17.7 (T)69.9 (suchiya N, Mitsui H, et al. )54.8 (Association of HLA-)]TJ
1.675 -1.25 Td
(B39 with HLA-B27-negative ankylosing spondylitis and)Tj
T*
(pauciarticular juvenile rheumatoid arthritis in Japanese patients:)Tj
T*
[(evidence for a role of the peptide-anchoring B pocket. )54.8 (Arthritis)]TJ
0 Tc T*
(Rheum 1995;38:1672-7.)Tj
-0.00011 Tc -1.675 -1.25 Td
[(9.)-875.1 (Salvarani C, Macchioni P)110.7 (, Cremonesi )17.7 (T)74 (, et al. )17.7 (The cervical spine in)]TJ
1.675 -1.25 Td
(patients with psoriatic arthritis: a clinical radiological and)Tj
T*
[(immunogenetics study)64.8 (. )54.8 (Ann Rheum Dis 1992;51:73-7.)]TJ
-2.175 -1.25 Td
[(10.)-875.1 (Gladman D, Farewell )17.7 (V)128.9 (.)-0.1 ( )17.7 (The role of HLA)-220.2 (antigens as indicators of)]TJ
2.175 -1.25 Td
(disease progression in psoriatic arthritis. Multivariate relative risk)Tj
T*
[(model. )54.8 (Arthritis Rheum 1995;38:845-50.)]TJ
-2.1381 -1.25 Td
[(1)36.8 (1)-0.1 (.)-875.1 (Lopez de Castro JA. Structure, function and disease association of)]TJ
2.1381 -1.25 Td
(HLA-B27. Curr Opin Rheumatol 1994;6:371-7.)Tj
-2.175 -1.25 Td
[(12.)-875.1 (Madden DR, Gor)17.7 (ga JC, Strominger JL, )17.7 (W)39.8 (iley DC. )17.7 (The three-)]TJ
2.175 -1.25 Td
(dimensional structure of HLA-B27 at 2.1: a resolution suggests a)Tj
T*
(general mechanism for tight peptide binding to MHC. Cell)Tj
0 Tc 0 Tw T*
(1992;70:1035-48.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(13.)-875.1 (Sobao )36.8 (Y)128.9 (,)-0.1 ( )17.7 (T)69.9 (suchiya N, )17.7 (T)69.9 (akiguchi M, )17.7 (T)69.9 (okunaga K. Overlapping)]TJ
2.175 -1.25 Td
(peptide-binding specificities of HLA-B27 and B39: evidence for a)Tj
T*
(role of peptide supermotif in the pathogenesis of)Tj
T*
[(spondylarthropathies. )54.8 (Arthritis Rheum 1999;42:175-81.)]TJ
ET
0 0 0 0 scn
408 770 150 -25 re
f*
BT
0 0 0 1 scn
/T1_3 1 Tf
0 Tw 20.37 0 0 21 461.9631 753.6089 Tm
(\002\003\003\002\004\005\006\007\004\016)Tj
ET
/CS0 CS 0 0 0 1 SCN
54 54 m
558 54 l
S
BT
/T1_1 1 Tf
0.02499 Tw 8 0 0 8 54.5 35.9844 Tm
(Bravo, et al: HLA-B*39 in brucellosis)Tj
0 Tc 0 Tw 60.9375 -0.0313 Td
(1053)Tj
ET
0 0 0 0 scn
/GS0 gs
109.22 59.09 396.48 -10.84 re
f*
0.5 w
109.22 59.09 396.48 -10.84 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 0 0 rg
/GS2 gs
/T1_4 8 Tf
117.48 51 Td
(Personal, non-commercial use only. The Journal of Rheumatology Copyrig\
ht \251 2003. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_5 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
26 0 obj
<>
endobj
27 0 obj
<>
endobj
47 0 obj
<>
endobj
28 0 obj
<>
endobj
71 0 obj
<>
endobj
83 0 obj
<>
endobj
29 0 obj
<>
endobj
32 0 obj
<>
endobj
31 0 obj
<>stream
H\Mk@=$nPmEd" k<
ͳ_yI\֮U}Q5=X:Ej>ZuvPIXF֮UYNm<6h۾I?[wP_<G؍JBL>lm}ͧV;*5-T®;6ɴ,7,sT/HcY
!g9%+)@.f30GE3 l,ȕF Ff4hc{9 %ͱ Jbk Jbk^ Jbk G%-pAQi$E<$&(m;%@ s}+$x,I8$9\RW}\azkυ5Z}|}hq0ɯ ~cR
endstream
endobj
30 0 obj
<>stream
H\iTSwo4˵q̽uSJ;-BX@@,!H"HC=݈PVEԩԣ?mC?̇}ÏPW
e!oŤd$
v1olw9N#F"oeeՌkpi9|d;vqtrAOo@nLl\')TAZ0#SDA(:0dJdd
Av!ً +#Aw%d7DQx+FWQ4quox2io|;V.ʰG=l\_+9yU5Czp_6R+eݽ5Pj:2Aha#5ɧRk@S4PMBH
2iL[ܒ/kjl(K惥ZL1>νO]j%G
6s}j6W_E_t'DQ@VV~;׀68\'ۓ؟
l͇a0~K3;,f2R7ͤYؚhp;zVb} ؠ7<*Nߒ@&s+w
~@Q:VCPY:cFT
E9b?b6qT.'@Y\,r v)!C\3Y*U*H%RE"M1O*x[b0
L'u p;C [^N7_c4
K D9?R( R\R*UlAځVV;{F
`pԲ`j&L @j